Is Walgreen a Buy Today?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Shares of Walgreen (NYSE: WAG  ) climbed more than 10% yesterday on news that the drugstore and pharmacy benefits manager Express Scripts (Nasdaq: ESRX  ) finally reunited after a messy breakup earlier this year. The market is rewarding both of these stocks on their new multiyear agreement. However, I don't think Walgreen is out of the woods just yet.

Let's take a closer look at the implications of the new reimbursement deal and see why investors may want to sit on the sidelines before jumping into shares of Walgreen.

The damage is done
Relationships, especially professional ones, often require compromises between those involved. Unfortunately for Walgreen, it took nearly seven months to finally reach an understanding with Express Scripts -- a drawn-out process that cost the country's largest drugstore chain billions in sales.

In addition to lost revenue, the dispute also boosted business for Walgreen's competitors, including CVS Caremark (NYSE: CVS  ) and Rite Aid (NYSE: RAD  ) . That's because after the pharmacy retailer refused to renew its contract with Express Scripts, millions of patients in the Express network were forced to fill their prescriptions elsewhere.

Aggressive marketing campaigns by both CVS and Rite Aid earlier this year also didn't help. CVS ran an ad saying: "Have you been notified that your pharmacy may stop accepting your Express Scripts insurance? We can help." Now it's Walgreen's turn to incentivize customers to return, which won't be easy. 

Playing nice
Having now made peace with the pharmacy benefits manager, Walgreen is hoping to pick up the pieces. However, being back in the Express Scripts network may not be enough for Walgreen to win back lost members.

In fact, CEO Larry Merlo of rival CVS is confident that his company can hold on to at least half of the customers it's gained so far from Walgreen. And who can blame him? Anyone who has ever transferred prescriptions from one pharmacy to another knows how frustrating the process can be.

This is likely to have a negative impact on the company's earnings in the quarters to come.

All told, I expect pharmacy sales at Walgreen to continue to slide in the second half of the year, despite its newly inked contract with Express Scripts. While the stock was riding higher this week on the news, let's see how it measures up to industry peers year to date. 

WAG Chart

WAG data by YCharts

Walgreen hasn't been an investor favorite in recent months. At the same time, shares of the pharmacy retailer boast an attractive dividend yield of 3.2% and trade at just over 11 times earnings. It's also worth considering that Walgreen has a rich history of rewarding patient shareholders. Last month, management raised its quarterly payout by more than 22% to just over $0.27 a share, or $1.10 annually.

But wait, there's more
Enticing dividends and strong financials bode well for investors. However, to be fair we need also consider the added risks brought on by Walgreen's recent $6.7 billion splurge on a portion of European drugstore chain Alliance Boots. That's an expensive bid for what is said will be a 45% stake in Boots.

As if gaining major European exposure during a time of such uncertainty in the region isn't bad enough, Walgreen also plans to take on billions in debt to fund the cash-and-stock deal. At this point, I'm finding it difficult to see the value in what appears to be a risk-all play.

Take it or leave it?
With all the pros and cons, what's an investor to do? Walgreen gets high marks for its position as an industry leader and overall healthy balance sheet. Still, there's no denying that management's initial decision to drop Express Scripts was a bonehead move that will probably haunt Walgreen into fiscal 2013. The seemingly sporadic merger with the European pharmacy giant also adds unnecessary risk to this name.

Given these reasons, I think investors would be wise to sit this one out -- at least while Walgreen navigates new British drug regulations and works toward rebuilding its status within the Express Scripts network. In the meantime, I invite you discover three winning stocks with solid dividend payouts in this free report from The Motley Fool. Get instant access to this free report, while it's still available.

Fool contributor Tamara Rutter owns no shares of any companies mentioned in this column. Follow her on Twitter, where she uses the handle @TamaraRutter, for more Foolish insights and investing advice. The Motley Fool owns shares of Express Scripts. Motley Fool newsletter services have recommended buying shares of Express Scripts. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 21, 2012, at 4:36 PM, JBKirtley wrote:

    Chain Drug Store News credits the CEO of Alliance-Boots with being the sharpest in the business. And while Wassom of WAG has been vilified by both shareholders and employees, he did get a better deal than what was originally offered by ESI. Pressure on ESI resulting from WAG signing some of their expiring agreements to direct contracts leveled the playing field that analysts were decidedly tilting to ESI. The biggest mistake in evaluating WAG 's buy status is failing to see the company as an innovator and first mover in the retail pharmacy business. The prescription outlet model is dying. In five years, the rest will be trying to catch WAG when its innovative community care centers reap profits from patient services that will make those from dispensing fees look like peanuts. Full disclosure: I do not own WAG stock, but have it on my watch list.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1952060, ~/Articles/ArticleHandler.aspx, 10/24/2016 1:30:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
WBA $81.57 Up +0.55 +0.68%
Walgreens Boots Al… CAPS Rating: ****
CVS $87.41 Up +0.11 +0.13%
CVS Health CAPS Rating: ****
ESRX $69.61 Down -1.43 -2.01%
Express Scripts CAPS Rating: *****
RAD $7.04 Down -0.07 -0.98%
Rite Aid CAPS Rating: ****